Overview

A Phase II Randomized Trial of Bicalutamide in Patients Receiving Intravesical BCG for Non-muscle Invasive Bladder Cancer

Status:
Not yet recruiting

Trial end date:
2026-12-31

Target enrollment:

Participant gender:

Summary

This is a phase II randomized controlled clinical trial comparing standard induction BCG versus bicalutamide and standard induction BCG among patients with non-muscle invasive bladder cancer.

Phase:

Phase 2

Details

Lead Sponsor:

CHU de Quebec-Universite Laval

Collaborator:

Canadian Institutes of Health Research (CIHR)

Treatments:

Androgen Antagonists
Bicalutamide
Nonsteroidal Anti-Androgens